Latest & greatest articles for esomeprazole

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on esomeprazole or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on esomeprazole and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for esomeprazole

1. Esomeprazole to treat women with preterm preeclampsia: a randomized placebo controlled trial

Esomeprazole to treat women with preterm preeclampsia: a randomized placebo controlled trial 30055127 2018 10 01 1097-6868 219 4 2018 Oct American journal of obstetrics and gynecology Am. J. Obstet. Gynecol. Esomeprazole to treat women with preterm preeclampsia: a randomized placebo controlled trial. 388.e1-388.e17 S0002-9378(18)30606-9 10.1016/j.ajog.2018.07.019 Preterm preeclampsia has a high rate of fetal death or disability. There is no treatment to slow the disease, except delivery (...) . Preclinical studies have identified proton pump inhibitors as a possible treatment. The purpose of this study was to examine whether esomeprazole could prolong pregnancy in women who have received a diagnosis of preterm preeclampsia. We performed a double-blind, randomized controlled trial at Tygerberg Hospital in South Africa. Women with preterm preeclampsia (gestational age 26 weeks+0 days to 31 weeks+6 days) were assigned randomly to 40-mg daily esomeprazole or placebo. The primary outcome

EvidenceUpdates2018

2. Esomeprazole

Esomeprazole Top results for esomeprazole - Trip Database or use your Google+ account Liberating the literature My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing (...) the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for esomeprazole The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines

Trip Latest and Greatest2018

3. Esomeprazole and aspirin in Barrett's oesophagus (AspECT): a randomised factorial trial.

Esomeprazole and aspirin in Barrett's oesophagus (AspECT): a randomised factorial trial. BACKGROUND: Oesophageal adenocarcinoma is the sixth most common cause of cancer death worldwide and Barrett's oesophagus is the biggest risk factor. We aimed to evaluate the efficacy of high-dose esomeprazole proton-pump inhibitor (PPI) and aspirin for improving outcomes in patients with Barrett's oesophagus. METHODS: The Aspirin and Esomeprazole Chemoprevention in Barrett's metaplasia Trial had a 2 × 2

Lancet2018 Full Text: Link to full Text with Trip Pro

4. Efficacy and Safety of Once-Daily Esomeprazole for the Treatment of Gastroesophageal Reflux Disease in Neonatal Patients

Efficacy and Safety of Once-Daily Esomeprazole for the Treatment of Gastroesophageal Reflux Disease in Neonatal Patients 23800403 2013 08 26 2013 11 18 2013 11 21 1097-6833 163 3 2013 Sep The Journal of pediatrics J. Pediatr. Efficacy and safety of once-daily esomeprazole for the treatment of gastroesophageal reflux disease in neonatal patients. 692-8.e1-2 10.1016/j.jpeds.2013.05.007 S0022-3476(13)00547-7 To evaluate the efficacy and safety of proton pump inhibitors in infants aged <1 year (...) with gastroesophageal reflux disease (GERD). In this randomized, double-blind, placebo-controlled multicenter study, neonates (premature to 1 month corrected age; n = 52) with signs and symptoms of GERD received esomeprazole 0.5 mg/kg or placebo once daily for up to 14 days. Change from baseline in the total number of GERD symptoms (from video monitoring) and GERD-related signs (from cardiorespiratory monitoring) was assessed with simultaneous esophageal pH, impedance, cardiorespiratory, and 8-hour video monitoring

EvidenceUpdates2013

5. Randomized Controlled Trial Comparing Aerosolized Swallowed Fluticasone to Esomeprazole for Esophageal Eosinophilia

Randomized Controlled Trial Comparing Aerosolized Swallowed Fluticasone to Esomeprazole for Esophageal Eosinophilia 23399553 2013 03 05 2013 05 20 2015 11 19 1572-0241 108 3 2013 Mar The American journal of gastroenterology Am. J. Gastroenterol. Randomized controlled trial comparing aerosolized swallowed fluticasone to esomeprazole for esophageal eosinophilia. 366-72 10.1038/ajg.2012.443 Patients with clinical symptoms of esophageal dysfunction and dense eosinophilic infiltration (...) of the esophageal mucosa are suspected to have eosinophilic esophagitis (EoE). Topical steroids are often used as first-line therapy for EoE, although some patients respond clinically to proton pump inhibitors (PPIs). The purpose of this study was to compare the histological and clinical response of patients with esophageal eosinophilia treated with aerosolized swallowed fluticasone propionate vs. esomeprazole. This prospective single-blinded randomized controlled trial enrolled newly diagnosed patients

EvidenceUpdates2013

6. Nexium Control - esomeprazole

Nexium Control - esomeprazole 7 Westferry Circus ? Canary Wharf ? London E14 4HB ? United Kingdom An agency of the European Union Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7418 8613 E-mail info@ema.europa.eu Website www.ema.europa.eu © European Medicines Agency, 2013. Reproduction is authorised provided the source is acknowledged. 27 June 2013 EMA/498929/2013 Committee for Medicinal Products for Human Use (CHMP) Assessment report Nexium Control International non-proprietary name (...) : esomeprazole Procedure No. EMEA/H/C/002618 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. Assessment report EMA/498929/2013 Page 2/70 Product information Marketing authorisation application Name of the medicinal product: Nexium Control Applicant: AstraZeneca AB Building 411A, Floor 4 S - 151 85 Södertälje SWEDEN Active substance: esomeprazole (as magnesium trihydrate) International Nonproprietary Name/Common Name: esomeprazole Pharmaco

European Medicines Agency - EPARs2013

7. Esomeprazole Strontium Delayed-Release Capsules

Esomeprazole Strontium Delayed-Release Capsules Drug Approval Package: Brand Name (Generic Name) NDA # Drug Approval Package U.S. Food & Drug Administration Enter Search terms Drug Approval Package - Esomeprazole Strontium Delayed-Release Capsules Company: Hanmi USA Inc. Application No.: 202342 Approval Date: 08/06/2013 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF

FDA - Drug Approval Package2013

8. Esomeprazole (Nexium® IV)

Esomeprazole (Nexium® IV) Esomeprazole (Nexium® IV) Esomeprazole (Nexium® IV) All Wales Medicines Strategy Group (AWMSG) Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation All Wales Medicines Strategy Group (AWMSG). Esomeprazole (Nexium® IV) Penarth: All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG (...) ). AWMSG Secretariat Assessment Report Advice No. 0712. 2012 Authors' conclusions Esomeprazole (Nexium® IV) is recommended as an option for use within NHS Wales for gastric antisecretory treatment when the oral route is not possible, such as gastro-oesophageal reflux disease (GORD) in patients with erosive reflux oesophagitis and/or severe symptoms of reflux for children and adolescents aged 1–18 years of age. AWMSG is of the opinion that esomeprazole (Nexium® IV) is suitable for specialist only

Health Technology Assessment (HTA) Database.2012

9. Esomeprazole Alone Compared with Esomeprazole Plus Aspirin for the Treatment of Aspirin-Related Peptic Ulcers

Esomeprazole Alone Compared with Esomeprazole Plus Aspirin for the Treatment of Aspirin-Related Peptic Ulcers 22508148 2012 07 05 2012 10 24 2015 11 19 1572-0241 107 7 2012 Jul The American journal of gastroenterology Am. J. Gastroenterol. Esomeprazole alone compared with esomeprazole plus aspirin for the treatment of aspirin-related peptic ulcers. 1022-9 10.1038/ajg.2012.87 Aspirin-related peptic ulcers are a common disorder. However, whether or not aspirin should be continued during treatment (...) for aspirin-related ulcers remains unclear. To compare esomeprazole alone with esomeprazole plus aspirin in the treatment of aspirin-related peptic ulcers and to investigate the independent factors associated with the failure of ulcer healing. From January 2008 to July 2011, patients with aspirin-related peptic ulcers were randomized to receive esomeprazole (40 mg per day) alone or esomeprazole (40 mg per day) plus aspirin (100 mg per day) for 8 weeks. The subjects with Helicobacter pylori infection were

EvidenceUpdates2012

10. Randomised controlled trial: Laparoscopic antireflux surgery and esomeprazole similarly efficacious for symptoms in people with gastro-oesophageal reflux disease who respond well to proton pump inhibitors

Randomised controlled trial: Laparoscopic antireflux surgery and esomeprazole similarly efficacious for symptoms in people with gastro-oesophageal reflux disease who respond well to proton pump inhibitors Laparoscopic antireflux surgery and esomeprazole similarly efficacious for symptoms in people with gastro-oesophageal reflux disease who respond well to proton pump inhibitors | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use (...) of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Laparoscopic antireflux surgery and esomeprazole similarly efficacious for symptoms in people

Evidence-Based Medicine (Requires free registration)2012

11. Naproxen + esomeprazole (Vimovo) - the symptomatic treatment of osteoarthritis (OA), rheumatoid arthritis (RA) and ankylosing spondylitis (AS)

Naproxen + esomeprazole (Vimovo) - the symptomatic treatment of osteoarthritis (OA), rheumatoid arthritis (RA) and ankylosing spondylitis (AS)

Scottish Medicines Consortium2011

12. Prevention of peptic ulcers with esomeprazole in patients at risk of ulcer development treated with low-dose acetylsalicylic acid: a randomised, controlled trial (OBERON).

Prevention of peptic ulcers with esomeprazole in patients at risk of ulcer development treated with low-dose acetylsalicylic acid: a randomised, controlled trial (OBERON). 21415072 2011 04 25 2011 07 01 2016 12 15 1468-201X 97 10 2011 May Heart (British Cardiac Society) Heart Prevention of peptic ulcers with esomeprazole in patients at risk of ulcer development treated with low-dose acetylsalicylic acid: a randomised, controlled trial (OBERON). 797-802 10.1136/hrt.2010.217547 To determine (...) whether once-daily esomeprazole 40 mg or 20 mg compared with placebo reduces the incidence of peptic ulcers over 26 weeks of treatment in patients taking low-dose acetylsalicylic acid (ASA) and who are at risk for ulcer development. Multinational, randomised, blinded, parallel-group, placebo-controlled trial. Cardiology, primary care and gastroenterology centres (n=240). Helicobacter pylori-negative patients taking daily low-dose ASA (75-325 mg), who fulfilled one or more of the following criteria

EvidenceUpdates2011 Full Text: Link to full Text with Trip Pro

13. Esomeprazole with clopidogrel reduces peptic ulcer recurrence, compared with clopidogrel alone, in patients with atherosclerosis

Esomeprazole with clopidogrel reduces peptic ulcer recurrence, compared with clopidogrel alone, in patients with atherosclerosis 21144850 2011 03 07 2011 05 09 2016 11 25 1528-0012 140 3 2011 Mar Gastroenterology Gastroenterology Esomeprazole with clopidogrel reduces peptic ulcer recurrence, compared with clopidogrel alone, in patients with atherosclerosis. 791-8 10.1053/j.gastro.2010.11.056 We performed a prospective, randomized, controlled study to compare the combination of esomeprazole (...) and clopidogrel vs clopidogrel alone in preventing recurrent peptic ulcers in patients with atherosclerosis and a history of peptic ulcers. We also investigated the effects of esomeprazole on the antiplatelet action of clopidogrel. From January 2008 to January 2010, long-term clopidogrel users with histories of peptic ulcers who did not have peptic ulcers at an initial endoscopy examination were assigned randomly to receive the combination of esomeprazole (20 mg/day, before breakfast) and clopidogrel (75 mg

EvidenceUpdates2011

14. Laparoscopic antireflux surgery vs esomeprazole treatment for chronic GERD: the LOTUS randomized clinical trial.

Laparoscopic antireflux surgery vs esomeprazole treatment for chronic GERD: the LOTUS randomized clinical trial. 21586712 2011 05 18 2011 05 20 2016 10 17 1538-3598 305 19 2011 May 18 JAMA JAMA Laparoscopic antireflux surgery vs esomeprazole treatment for chronic GERD: the LOTUS randomized clinical trial. 1969-77 10.1001/jama.2011.626 Gastroesophageal reflux disease (GERD) is a chronic, relapsing disease with symptoms that have negative effects on daily life. Two treatment options are long-term (...) medication or surgery. To evaluate optimized esomeprazole therapy vs standardized laparoscopic antireflux surgery (LARS) in patients with GERD. The LOTUS trial, a 5-year exploratory randomized, open, parallel-group trial conducted in academic hospitals in 11 European countries between October 2001 and April 2009 among 554 patients with well-established chronic GERD who initially responded to acid suppression. A total of 372 patients (esomeprazole, n = 192; LARS, n = 180) completed 5-year follow-up

JAMA2011

15. The gain in quality-adjusted life months by switching to esomeprazole in those with continued reflux symptoms in primary care: EncomPASS--a cluster-randomized trial

The gain in quality-adjusted life months by switching to esomeprazole in those with continued reflux symptoms in primary care: EncomPASS--a cluster-randomized trial 20842110 2010 11 04 2010 11 29 2015 11 19 1572-0241 105 11 2010 Nov The American journal of gastroenterology Am. J. Gastroenterol. The gain in quality-adjusted life months by switching to esomeprazole in those with continued reflux symptoms in primary care: EncomPASS--a cluster-randomized trial. 2341-6 10.1038/ajg.2010.368 (...) esomeprazole in those with continued symptoms on another PPI or H(2) receptor antagonist therapy would be cost effective. We expressed the data in terms of cost per quality-adjusted life months (QALM), as this was a 4-week trial. This is a multicenter, cluster-randomized, open-label study in primary care physician centers across Canada. Primary care physician centers were randomized to intervention or control arms. Patients on acid-suppressing medication were identified from primary care records and asked

EvidenceUpdates2010

17. Cost effectiveness of high-dose intravenous esomeprazole for peptic ulcer bleeding

Cost effectiveness of high-dose intravenous esomeprazole for peptic ulcer bleeding Cost effectiveness of high-dose intravenous esomeprazole for peptic ulcer bleeding Cost effectiveness of high-dose intravenous esomeprazole for peptic ulcer bleeding Barkun AN, Adam V, Sung JJ, Kuipers EJ, Mossner J, Jensen D, Stuart R, Lau JY, Naucler E, Kilhamn J, Granstedt H, Liljas B, Lind T Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED (...) . Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study assessed the cost-effectiveness of high-dose intravenous esomeprazole, versus no intravenous proton-pump inhibitor, to prevent re-bleeding, after successful endoscopic haemostasis, in patients with peptic ulcer bleeding. The authors concluded that high-dose intravenous esomeprazole improved

NHS Economic Evaluation Database.2010

18. Vimovo (naproxen/esomeprazole magnesium) Delayed Release Tablets

Vimovo (naproxen/esomeprazole magnesium) Delayed Release Tablets Drug Approval Package: Brand Name (Generic Name) NDA # Drug Approval Package U.S. Food & Drug Administration Enter Search terms Drug Approval Package - Vimovo (naproxen/esomeprazole magnesium) Delayed Release Tablets Company: Pozen Application No.: 022511 Approval Date: 4/30/2010 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF

FDA - Drug Approval Package2010

20. H. pylori eradication prevents the progression of gastric intestinal metaplasia in reflux esophagitis patients using long-term esomeprazole

H. pylori eradication prevents the progression of gastric intestinal metaplasia in reflux esophagitis patients using long-term esomeprazole 19436275 2009 07 03 2009 07 24 2013 11 21 1572-0241 104 7 2009 Jul The American journal of gastroenterology Am. J. Gastroenterol. H. pylori eradication prevents the progression of gastric intestinal metaplasia in reflux esophagitis patients using long-term esomeprazole. 1642-9 10.1038/ajg.2009.172 This study aimed to determine whether Helicobacter pylori (...) eradication limits the progression of precancerous changes, manifested as intestinal metaplasia (IM), in patients with reflux esophagitis using long-term esomeprazole. Three hundred twenty-five reflux esophagitis patients were enrolled and randomly assigned to (i) the H. pylori-positive eradication group receiving 1-week triple therapy (n=105); (ii) H. pylori-positive non-eradication controls (n=105); and (iii) H. pylori-negative controls (n=115). All the patients received continuous esomeprazole until

EvidenceUpdates2009